Effect of icariin in a rat model of colchicine-induced cognitive deficit: role of β-amyloid proteolytic enzymes

References

• Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370–8.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.
   PubMed Web of Science ®Google Scholar
• Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23(26):8844–53.
   PubMed Web of Science ®Google Scholar
• Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med. 2012;2(6):a006379.
   PubMed Web of Science ®Google Scholar
• Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292(5521):1550–2.
   PubMed Web of Science ®Google Scholar
• Kurochkin IV, Guarnera E, Berezovsky IN. Insulin-degrading enzyme in the fight against Alzheimer's disease. Trends Pharmacol Sci. 2018;39(1):49–58.
   PubMed Web of Science ®Google Scholar
• Cynis H, Lichtenthaler SF, Wagner L, Demuth HU. Proteases in Alzheimer’s disease. In: Brix K, Stöcker W, editor. Proteases: structure and function. New York: Springer-Verlag Wien; 2013. p. 319–71.
   Google Scholar
• Joy T, Rao MS, Madhyastha S, Pai K. Effect of N-acetyl cysteine on intracerebroventricular colchicine induced cognitive deficits, beta amyloid pathology, and glial cells. Neurosci J. 2019;2019:7547382.
   PubMedGoogle Scholar
• Kumar A, Seghal N, Vaidu PS, Padi SS, Goyal R. Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type. Pharmacol Rep. 2007;59(3):274–83.
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Luo XY, Sun YX, Wu W, Liu CM, Liu ZQ, et al. The antioxidative effect of icariin in human erythrocytes against free-radical-induced haemolysis. J Pharm Pharmacol. 2004;56(12):1557–62.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang G, He J, Yang Q, Li D, Li J, et al. Icariin attenuates neuroinflammation and exerts dopamine neuroprotection via an Nrf2-dependent manner. J Neuroinflam. 2019;16(1):92.
   PubMedGoogle Scholar
• Veerendra Kumar MH, Gupta YK. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav. 2002;73(3):565–71.
   PubMed Web of Science ®Google Scholar
• Mangrulkar SV, Selote RD, Chaple DR. Antiamnesic effect of berberine in colchicines induced experimental Alzheimer’s disease model. Int J Pharm Bio Sci. 2013;4(3):618–28.
   Google Scholar
• Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego (CA): Academic Press; 1986.
   Google Scholar
• Mohamed AR, Soliman GY, Ismail CA, Hazem FM. Neuroprotective role of vitamin D3 in colchicine-induced Alzheimer’s disease in rats. Alex J Med. 2015;51(2):127–36.
   Web of Science ®Google Scholar
• Nassar SZ, Badae NM, Issa YA. Effect of amylin on memory and central insulin resistance in a rat model of Alzheimer's disease. Arch Physiol Biochem. 2020;126(4):326–34.
   PubMed Web of Science ®Google Scholar
• Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297(5868):681–3.
   PubMed Web of Science ®Google Scholar
• Spijker S. Dissection of rodent brain regions. In: Li KW, editor. Neuroproteomics. New York: Humana Press; 2011. p. 23–6.
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.
   PubMed Web of Science ®Google Scholar
• Shim DJ, Yang L, Reed JG, Noebels JL, Chiao PJ, Zheng H. Disruption of the NF-κB/IκBα autoinhibitory loop improves cognitive performance and promotes hyperexcitability of hippocampal neurons. Mol Neurodegener. 2011;6:42.
   PubMed Web of Science ®Google Scholar
• Yin C, Deng Y, Gao J, Li X, Liu Y, Gong Q. Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats. Neuroscience. 2016;328:69–79.
   PubMed Web of Science ®Google Scholar
• Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4–15. doi:10.1016/j.peptides.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Sheng C, Xu P, Zhou K, Deng D, Zhang C, Wang Z, et al. Icariin attenuates synaptic and cognitive deficits in an Aβ(1-42)-induced rat model of Alzheimer's disease. Biomed Res Int. 2017;2017:7464872.
   PubMed Web of Science ®Google Scholar
• Yan L, Deng Y, Gao J, Liu Y, Li F, Shi J, et al. Icariside II effectively reduces spatial learning and memory impairments in Alzheimer's disease model mice targeting beta-amyloid production. Front Pharmacol. 2017;8:106.
   Google Scholar
• Liu S, Li X, Gao J, Liu Y, Shi J, Gong Q. Icariside II, a phosphodiesterase-5 inhibitor, attenuates beta-amyloid-induced cognitive deficits via BDNF/TrkB/CREB signaling. Cell Physiol Biochem. 2018;49(3):985.
   Google Scholar
• Nie J, Luo Y, Huang XN, Gong Q-H, Wu Q, Shi J-S, et al. Icariin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol. 2010;626(2-3):213–8.
   PubMed Web of Science ®Google Scholar
• Li F, Dong HX, Gong QH, Wu Q, Jin F, Shi JS. Icariin decreases both APP and Aβ levels and increases neurogenesis in the brain of Tg2576 mice. Neuroscience. 2015;304:29–35.
   PubMed Web of Science ®Google Scholar
• Oefner C, D'Arcy A, Hennig M, Winkler FK, Dale GE. Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol. 2000;296(2):341–9.
   PubMed Web of Science ®Google Scholar
• Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol. 2005;64(5):378–85.
   PubMed Web of Science ®Google Scholar
• Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res. 2007;32(10):1741–8.
   PubMed Web of Science ®Google Scholar
• Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, et al. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep. 2013;3:1472.
   PubMed Web of Science ®Google Scholar
• Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park J-S, et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. Brain Res. 2013;1529:113–24.
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol. 2004;164(4):1425–34.
   PubMed Web of Science ®Google Scholar
• Zipfel P, Rochais C, Baranger K, Rivera S, Dallemagne P. Matrix metalloproteinases as new targets in Alzheimer's disease: opportunities and challenges. J Med Chem. 2020;63(19):10705–25.
   PubMed Web of Science ®Google Scholar
• Boon L, Ugarte-Berzal E, Vandooren J, Opdenakker G. Protease propeptide structures, mechanisms of activation, and functions. Crit Rev Biochem Mol Biol. 2020;55(2):111–65.
   PubMed Web of Science ®Google Scholar
• Young D, Das N, Anowai A, Dufour A, et al. Matrix metalloproteases as influencers of the cells’ social media. Int J Mol Sci. 2019;20(16):3847.
   PubMed Web of Science ®Google Scholar
• Ciccone L, Vandooren J, Nencetti S, Orlandini E. Natural marine and terrestrial compounds as modulators of matrix metalloproteinases-2 (MMP-2) and MMP-9 in Alzheimer's disease. Pharmaceuticals (Basel). 2021;14(2):86.
   PubMedGoogle Scholar
• Wang XX, Tan MS, Yu JT, Tan L. Matrix metalloproteinases and their multiple roles in Alzheimer's disease. Biomed Res Int. 2014;2014:908636.
   PubMed Web of Science ®Google Scholar
• Jiang P, Li C, Xiang Z, Jiao B. Tanshinone IIA reduces the risk of Alzheimer's disease by inhibiting iNOS, MMP-2 and NF-κBp65 transcription and translation in the temporal lobes of rat models of Alzheimer's disease. Mol Med Rep. 2014;10(2):689–94.
   PubMed Web of Science ®Google Scholar
• Zong N, Li F, Deng Y, Shi J, Jin F, Gong Q, et al. Icariin, a major constituent from epimedium brevicornum, attenuates ibotenic acid-induced excitotoxicity in rat hippocampus. Behav Brain Res. 2016;313:111–9.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Xu L, Cheng Y. Neuroprotective activity of icariin against hypoxic-ischemic brain injury in neonatal rats. Int J Pharmacol. 2019;15:829–36.
   Google Scholar
• Marques MA, Kulstad JJ, Savard CE, Green PS, Lee SP, Craft S, et al. Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system. J Alzheimers Dis. 2009;16(2):325–9.
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295(5563):2264–7.
   PubMed Web of Science ®Google Scholar
• Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, et al. Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice. J Neurosci. 2013;33(6):2457–64.
   PubMed Web of Science ®Google Scholar